Growth Stage

Unlocking Biotech Potential with Cellular Restoration

Unlocking Biotech Potential with Cellular Restoration


Funding data not publicly available

Dealmaker Securities

Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common


Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Beverly Hills, California

Business Type


PhorMed, with a valuation of $52.5 million, is raising funds on Dealmaker Securities. It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells and is developing a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study with positive outcomes and is in Phase 2 now. Ben Chang founded PhorMed in May 2019. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, operations, research and development, general overhead expenses, and company employment.

Summary Profit and Loss Statement

FY 2022 FY 2021












Net Income



Summary Balance Sheet

FY 2022 FY 2021




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 10/27/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
PhorMed 01/31/2024 Dealmaker Securities $52,523,767 - Equity - Common Active RegCF
PhorMed 08/17/2022 StartEngine $51,647,023 $243,864 Equity - Common Funded RegCF
PhorMed 03/25/2022 StartEngine $39,000,000 $2,450,528 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
PhorMed on Dealmaker Securities 2023
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $52,523,767
Price per Share: $1.00

Follow company

Follow PhorMed on Dealmaker Securities 2023

Buy PhorMed's Deal Report

PhorMed Deal Report

Get KingsCrowd’s comprehensive report on PhorMed including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether PhorMed is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the PhorMed deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge